Global Atopic Eczema Treatment Market Size, Future Scope, Growth Analysis, Forecast Report 2020-2026
According to Facts & Factors, the global Atopic Eczema Treatment market size is expected to surpass around USD 18,057.4 Million in 2019 to USD 34,089.3 million by 2026 and is expanding growth at a registered CAGR of 10.36% from 2020 to 2026.
Atopic dermatitis is an inflammatory skin condition that causes red, itchy, swollen, and broken skin. The affected area may leak white fluid, necessitating treatment. Atopic dermis is more common in children and can worsen as they grow older. A genetic mutation, environmental contamination, immune system dysfunction, and skin permeability issues all contribute to atopic dermatitis.
Request Access A full report is available at: https://www.fnfresearch.com/atopic-eczema-treatment-market
The primary causes of atopic dermatitis are dry skin, irritants, fatigue, allergies, infection, and heat/sweating. It’s important to remember that these only cause atopic dermatitis symptoms, not the disease itself. Atopic dermatitis (AD) is a common chronic skin disorder linked to other atopic diseases. Despite mounting evidence of a link with non-atopic conditions such as autoimmune disorders, data on many autoimmune diagnoses is limited.
Dermatological disorders are extremely common in various forms throughout the world. Skin diseases affected over 900 million people in 2017, according to the World Health Organisation. The most common of these diseases is atopic dermatitis, which affects over 300 million people worldwide. Children account for roughly one-quarter of the victims. The increased prevalence of this disease is expected to have a positive economic impact.
Increased understanding of the disease’s therapeutic options has aided the market’s survival in recent years. The availability of favourable reimbursement plans, as well as government initiatives to ensure quality and more affordable care, are expected to boost the sector. Developing country health growth and evolution would present new opportunities during the study period.
Treatment is required because the infected area produces white fluid. Atopic dermis typically begins in childhood and worsens with age. Genetics, environmental toxicity, immune system dysfunction, and skin permeability issues all contribute to atopic dermatitis.
The market is classified into three types: topical, oral, and injectable. Atopic eczema treatment market is estimated to be dominated by the Topicalcategory. The cream-based treatment solution makes the product easy to apply, which is expected to drive market demand in the coming years. Furthermore, the market is divided into application categories such as hospital pharmacies, retail pharmacies, online pharmacies, and others. According to estimates, retail pharmacies have the largest market share of the atopic eczema market. However, due to mobile phone penetration and the emergence of numerous medicine delivery startups, online pharmacies are expected to grow at a significant CAGR.
North America was the largest market for the treatment of atopic dermatitis in 2019 due to new product releases, early treatment acceptance, and lifestyle improvements. According to the regional study, North America emerged as the leading market for atopic dermatitis due to higher treatment knowledge among the target population, early acceptance of novel drugs, and better reimbursement policies.
Europe has the second-largest market share. Large-scale R&D spending is the primary driver of demand in this area. Due to rising demand, the Asia-Pacific region is expected to grow the fastest between 2020 and 2026. The Asia-Pacific region is expected to grow the fastest between 2020 and 2026, owing to rising health expenditure and the availability of adequate care.
Major Key Players:
Encore Dermatology Inc., AbbieVie Inc., LEO Pharma A/S, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Bausch Health Companies Inc., GlaxoSmithKline plc., Sanofi S.A., Regeneron Pharmaceuticals Inc., LEO Pharma A/S, and Medimmune LLC. (AstraZeneca) are among the market leaders in atopic eczema treatment. The aforementioned companies’ primary market growth strategy is to invest in the research and development of new prescription products. For example, Sanofi Genzyme manufactures the Biologics medication DUPIXNET ®, which treats skin lesions and relieves scratching.
According to JAAD International, atopic eczema is the leading cause of skin-related impairment, affecting up to 24 percent of the global population, according to the 2017 Global Burden of Disease research database. Occupational dermatitis affects up to 23% of nurses, with daily hand washing and the use of protective gloves being major risk factors.
As a result of excessive use of personal protective equipment (PPE) and chronic stress, which exacerbates atopic eczema, the COVID-19 pandemic has increased cases of skin irritation and disease in health-care workers. Hand washing is a widely recommended method of preventing the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is expected to affect more people than just health-care workers as dermatitis cases increase. As a result, the atopic eczema treatment industry is expected to benefit from the global COVID-19 pandemic.
This report segments the Atopic Eczema Treatment market as follows:
Global Atopic Eczema Treatment Market: By Type Based Segmentation Analysis:
Global Atopic Eczema Treatment Market: By Application Segmentation Analysis
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Atopic Eczema Treatment Market: Regional Segmentation Analysis
- North America
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East & Africa
About Facts & Factors:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds.
Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Facts & Factors
USA: +1 347 690-0211 | UK: +44 2032 894158 | Japan: +81 50 5806 9039 | India: +91 73877 19999